Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
7.59
-0.29 (-3.68%)
At close: Mar 28, 2025, 4:00 PM
7.47
-0.12 (-1.58%)
After-hours: Mar 28, 2025, 7:22 PM EDT

Rocket Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
101.9670.3258.7741.7728.87
Upgrade
Research & Development
171.24186.34165.07124.48105.44
Upgrade
Operating Expenses
273.21256.66223.84166.25134.3
Upgrade
Operating Income
-273.21-256.66-223.84-166.25-134.3
Upgrade
Interest Expense
-1.89-1.88-1.86-2.98-6.97
Upgrade
Interest & Investment Income
8.275.293.893.072.15
Upgrade
EBT Excluding Unusual Items
-266.82-253.25-221.82-166.16-139.12
Upgrade
Merger & Restructuring Charges
--3---
Upgrade
Gain (Loss) on Sale of Investments
8.0810.65-0.05-2.91-0.58
Upgrade
Pretax Income
-258.75-245.6-221.86-169.07-139.7
Upgrade
Net Income
-258.75-245.6-221.86-169.07-139.7
Upgrade
Net Income to Common
-258.75-245.6-221.86-169.07-139.7
Upgrade
Shares Outstanding (Basic)
9584686355
Upgrade
Shares Outstanding (Diluted)
9584686355
Upgrade
Shares Change (YoY)
12.85%23.27%7.77%14.18%13.00%
Upgrade
EPS (Basic)
-2.73-2.92-3.26-2.67-2.52
Upgrade
EPS (Diluted)
-2.73-2.92-3.26-2.67-2.52
Upgrade
Free Cash Flow
-215.59-211.35-186.5-128.78-95.25
Upgrade
Free Cash Flow Per Share
-2.27-2.52-2.74-2.04-1.72
Upgrade
EBITDA
-263.83-249.56-217.58-160.88-133.16
Upgrade
D&A For EBITDA
9.387.16.275.371.15
Upgrade
EBIT
-273.21-256.66-223.84-166.25-134.3
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q